| S8925 |
Simurosertib |
Simurosertib (TAK-931), an oral cell division cycle 7 (CDC7)-selective inhibitor with an IC50<0.3 nM, induces S phase delay and replication stress and causes mitotic aberrations through centrosome dysregulation and chromosome missegregation, resulting in irreversible antiproliferative effects in cancer cells. |
Selective |
Cdc7, IC50: 0.3 nM |
| S7547 |
XL413 |
XL413 is a potent and selective cell division cycle 7 homolog (CDC7) kinase inhibitor with IC50 of 3.4 nM, showing 63-, 12- and 35-fold selectivity over CK2, Pim-1 and pMCM2, respectively.
|
Selective |
Cdc7, IC50: 3.4 nM |
| S6777 |
NSC95397 |
NSC 95397 is a potent, selective Cdc25 dual specificity phosphatase inhibitor with Ki of 32 nM, 96 nM, 40 nM for Cdc25A, Cdc25B and Cdc25C, respectively. NSC 95397 has IC50 of 22.3 nM, 56.9 nM and 125 nM for human Cdc25A, human Cdc25C and Cdc25B, respectively. NSC 95397 inhibits mitogen-activated protein kinase phosphatase-1 (MKP-1) and suppresses proliferation and induces apoptosis in colon cancer cells through MKP-1 and ERK1/2 pathway. |
Selective |
Cdc25A, Ki: 32 nM; Cdc25B, Ki: 96 nM; Cdc25C, Ki: 40 nM; Cdc25A, IC50: 22.3 nM; Cdc25B, IC50: 56.9 nM; Cdc25C, IC50: 125 nM |
| S6540 |
NG 52 |
NG-52 is a tri-substituted purine that binds to the ATP-binding site of yeast cyclin-dependent kinases, inhibiting Cdc28p and Pho85p with IC50s of 7 and 2 μM, respectively. |
Selective |
Cdc28p, IC50: 7 μM; Pho85p, IC50: 2 μM |
| S9650 |
LY3143921 hydrate |
LY3143921 hydrate is an orally administered ATP-competitive CDC7 inhibitor. |
Selective |
|
| S9605 |
Apcin |
Apcin (APC inhibitor) is an inhibitor of the E3 ligase activity of the mitotic anaphase-promoting complex/cyclosome (APC/C) that binds to Cdc20 and competitively inhibits the ubiquitylation of D-box-containing substrates. |
Selective |
|
| S7793 |
Purvalanol A |
Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively. Purvalanol A induces endoplasmic reticulum stress-mediated apoptosis and autophagy. |
Pan |
Cdc2/CyclinB, IC50: 4 nM |
| S0500 |
Purvalanol B |
Purvalanol B (NG-95) is a potent and selective inhibitor of cyclin-dependent kinase (CDK) with IC50 of 6 nM, 6 nM, 9 nM and 6 nM for cdc2-cyclin B, CDK2-cyclin A, CDK2-cyclin E and CDK5-p35, respectively. |
Pan |
cdc2-cyclin B, IC50: 6 nM |
| S2742 |
PHA-767491 HCl |
PHA-767491 (CAY10572, NMS 1116354) HCl is a potent ATP-competitive dual Cdc7/CDK9 inhibitor with IC50 of 10 nM and 34 nM in cell-free assays, respectively.It displays ~20-fold selectivity against CDK1/2 and GSK3-β, 50-fold selectivity against MK2 and CDK5, 100-fold selectivity against PLK1 and CHK2. |
Pan |
Cdc7, IC50: 10 nM |
| S1153 |
Roscovitine |
Roscovitine is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2. |
Pan |
Cdc2/CyclinB, IC50: 0.65 μM |
| S3224 |
Cinobufagin |
Cinobufagin (Cinobufagine), an active ingredient of Venenum Bufonis, inhibits tumor development. Cinobufagin increases ATM and Chk2 and decreases CDC25C, CDK1, and cyclin B. Cinobufagin inhibits PI3K, AKT and Bcl-2 while increases levels of cleaved caspase-9 and caspase-3. Thus, Cinobufagin induces cell cycle arrest at the G2/M phase and apoptosis. |
Pan |
|
